Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury
Dixon, B.; Schultz, M.J.; Hofstra, J.J.; Campbell, D.J.; Santamaria, J.D.

Published in:
Critical Care

DOI:
10.1186/cc9269

Link to publication

Citation for published version (APA):
https://doi.org/10.1186/cc9269

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Previously in this journal, we published a phase 1 study of nebulized heparin in patients with acute lung injury [1]. Patients were administered heparin at doses of 50,000, 100,000, 200,000, or 400,000 U/day for 2 days, and bronchoalveolar lavage (BAL) fluid samples were taken at baseline and after the last heparin dose. The study demonstrated a trend to reduced coagulation activation (prothrombin fragments) in BAL fluid after the last dose of nebulized heparin [1].

Following publication of these data, we were offered the possibility of further analysis of the BAL fluid with additional markers of coagulation activation, including thrombin-antithrombin complexes (TATcs), fibrin degradation products (FDPs), and plasminogen activator activity (PAI-1) levels. We wish to publish the results of this further analysis. The 400,000 U/day group had one patient more than the same group in the previously published data.

We found that TATc and FDP levels were significantly reduced in patients treated with 400,000 U/day of nebulized heparin, but not PAI-1 (Figure 1 overleaf). We believe that these data are important as they demonstrate for the first time that nebulized heparin significantly reduces coagulation activation in the lungs of critically ill patients with acute lung injury. This may be important knowledge as inflammatory mechanisms related to coagulation activation, such as hyaline membrane formation and microvascular thrombosis, may mediate lung injury [2,3].

Abbreviations
BAL, bronchoalveolar lavage; FDP, fibrin degradation product; PAI-1, plasminogen activator activity; TATc, thrombin-antithrombin complex.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Intensive Care, St Vincent's Hospital, 41 Victoria Parade, Fitzroy, Melbourne, Victoria, 3065, Australia. 2Department of Intensive Care Medicine & Laboratory of Experimental Intensive Care and Anesthesiology, The Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. 3St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, Melbourne, Victoria, 3065, Australia. 4Department of Medicine, The University of Melbourne, Clinical Sciences Building, 29 Regent Street, Fitzroy, Melbourne, Victoria, 3065, Australia.

Published: 20 October 2010

References

doi:10.1186/cc9269
Cite this article as: Dixon B, et al.: Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury. Critical Care 2010, 14:445.
Figure 1. Changes in markers of coagulation activation in bronchoalveolar fluid before and after 2 days of nebulized heparin. Each line represents a single patient (*$P < 0.01$, **$P < 0.001$, paired t test). FDP, fibrin degradation product; NS, not significant; PAI-1, plasminogen activator activity; TATc, thrombin-antithrombin complex.